SCHEMBL4124075

SCHEMBL4124075

CCc1ccc(NC(=O)Nc2cccc(F)c2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 14/20 0.68
NPC1 O15118 10/20 0.68
MEN1 O00255 9/20 0.68
KMT2A Q03164 9/20 0.68
MAPT P10636 5/20 0.68
SMN1; SMN2 Q16637 2/20 0.66
MTOR P42345 1/20 0.62
GAA P10253 2/20 0.60
SAE1 Q9UBE0 1/20 0.56
UBA2 Q9UBT2 1/20 0.56
CASP3 P42574 1/20 0.56
SENP7 Q9BQF6 1/20 0.56
TAAR1 Q96RJ0 1/20 0.55
GBA1 P04062 1/20 0.55
USP2 O75604 1/20 0.54
TP53 P04637 1/20 0.54
POLB P06746 1/20 0.54
ALOX15 P16050 1/20 0.54
HTT P42858 1/20 0.54
HSD17B10 Q99714 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4116592 0.88 MEN1 (0.60) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL29200431 0.86 MTOR (0.64) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL4104375 0.86 RAB9A (0.71) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL4118401 0.86 RAB9A (0.61) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL29200375 0.85 RAB9A (0.63) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL4107124 0.84 MEN1 (0.67) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL4117952 0.84 RAB9A (0.67) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL30851500 0.83 RAB9A (0.79) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL27193042 0.83 RAB9A (0.79) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL4117060 0.83 SAE1 (0.80) RAB9ANPC1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US claimed
EP-1804785-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2007-07-11 EP claimed
WO-2006049941-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2006-05-11 WO claimed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 RAB9A 815/4885NPC1 927/4885MEN1 3273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.